AML: Managing AEs With Venetoclax + Azacitidine

preview_player
Показать описание
A comprehensive review of identifying and managing adverse events tied to the combination of venetoclax and azacitidine in acute myeloid leukemia.

  1. Targeted Oncology
  2. targeted oncology
  3. oncology
  4. cancer
Рекомендации по теме
AML: Managing AEs 0:06:51

AML: Managing AEs With Venetoclax + Azacitidine

AML: Optimizing Selection 0:04:59

AML: Optimizing Selection and Use of Venetoclax + Azacitidine

Ideal patient for 0:00:43

Ideal patient for Venetoclax/Obinutuzumab combination | Dr. Jeff Sharman | Oncology Brothers #2023

Managing BCL2 Inhibitor 0:05:43

Managing BCL2 Inhibitor AEs in Chronic Lymphocytic Leukemia

Toxicity Management With 0:07:09

Toxicity Management With Venetoclax for CLL

Venetoclax in Higher-Risk 0:16:23

Venetoclax in Higher-Risk MDS/AML

Phase I trial 0:01:33

Phase I trial results for oral azacitidine and venetoclax in R/R AML

Part 2 - 0:32:51

Part 2 - How do I use BTKi for CLL management? - Dr. Nitin Jain, USA

IMGN632 is efficacious 0:02:20

IMGN632 is efficacious with venetoclax plus azacitidine in AML models

Comparing outcomes of 0:09:17

Comparing outcomes of 10-day decitabine with venetoclax vs. chemotherapy in AML based on fitness

Treating patients with 0:01:50

Treating patients with poor-risk cytogenetics with venetoclax and HMAs

Venetoclax plus HMAs 0:05:35

Venetoclax plus HMAs in IDH-mutant AML

Pevonedistat, venetoclax and 0:02:50

Pevonedistat, venetoclax and azacitidine for older AML patients

Current AML landscape: 0:24:14

Current AML landscape: Where do we stand in 2018?

Decitabine, venetoclax, and 0:01:23

Decitabine, venetoclax, and IDH inhibitor in IDH-mutated AML

How have venetoclax 0:02:32

How have venetoclax combinations changed the way we treat AML?

Role of chemotherapy 0:22:08

Role of chemotherapy in CLL management

Case 4: Observations 0:05:55

Case 4: Observations of HMA/Venetoclax in Trials

Venetoclax plus azacitidine 0:06:58

Venetoclax plus azacitidine for higher-risk MDS

BCL-2 Inhibitors With 0:04:10

BCL-2 Inhibitors With Hypomethylating Agents in AML

ACUTE MYELOBLASTIC LEUKAEMIA 1:26:49

ACUTE MYELOBLASTIC LEUKAEMIA

Seizing Opportunity in 1:41:20

Seizing Opportunity in AML: Realizing the Potential of Novel Tx in Diverse Patient Populations

Expert Video Report 0:06:53

Expert Video Report on Acute Myeloid Leukemia and high risk MDS from ASH 2020

Update on Venetoclax 0:24:09

Update on Venetoclax for CLL